Is Vyne Therapeutics Inc (VYNE) Stock About to Get Hot Monday?

Vyne Therapeutics Inc (VYNE) stock is up 52.60% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Vyne Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VYNE!

See Full VYNE Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With VYNE Stock Today?

Vyne Therapeutics Inc (VYNE) stock is up 21.26% while the S&P 500 is down -0.2% as of 1:06 PM on Monday, Mar 25. VYNE has risen $0.51 from the previous closing price of $2.42 on volume of 425,284 shares. Over the past year the S&P 500 is up 31.33% while VYNE has risen 9.33%. VYNE lost -$2.71 per share in the over the last 12 months. To screen for more stocks like Vyne Therapeutics Inc click here.

More About Vyne Therapeutics Inc

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Click Here to get the full Stock Report for Vyne Therapeutics Inc stock.